Cellular actions of the insulin-like growth factor binding proteins.

Senescence-messaging secretome: SMS-ing cellular stress. Nat Rev Cancer (2009) 5.02

The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer (2012) 4.72

Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol (2010) 3.75

The CCN family of proteins: structure-function relationships. Trends Biochem Sci (2008) 2.82

Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. J Clin Oncol (2008) 2.63

Sarcopenia: etiology, clinical consequences, intervention, and assessment. Osteoporos Int (2009) 2.53

Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med (2008) 2.33

Secreted and transmembrane wnt inhibitors and activators. Cold Spring Harb Perspect Biol (2013) 2.01

Insulin-like growth factor binding proteins 3 and 5 are overexpressed in idiopathic pulmonary fibrosis and contribute to extracellular matrix deposition. Am J Pathol (2005) 1.91

IGFBP3 suppresses retinopathy through suppression of oxygen-induced vessel loss and promotion of vascular regrowth. Proc Natl Acad Sci U S A (2007) 1.88

The many faces of insulin-like peptide signalling in the brain. Nat Rev Neurosci (2012) 1.87

Insulin-like growth factor-binding protein-5 (IGFBP-5): a critical member of the IGF axis. Biochem J (2006) 1.77

IGF binding protein-3 regulates hematopoietic stem cell and endothelial precursor cell function during vascular development. Proc Natl Acad Sci U S A (2007) 1.77

Unraveling insulin-like growth factor binding protein-3 actions in human disease. Endocr Rev (2009) 1.76

Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: results from intergroup trial N9741. Clin Cancer Res (2008) 1.76

IGF2: epigenetic regulation and role in development and disease. Cytokine Growth Factor Rev (2008) 1.73

Circulating insulin-like growth factors and IGF-binding proteins in PSA-detected prostate cancer: the large case-control study ProtecT. Cancer Res (2011) 1.71

Metformin: a therapeutic opportunity in breast cancer. Clin Cancer Res (2010) 1.70

Layer V cortical neurons require microglial support for survival during postnatal development. Nat Neurosci (2013) 1.70

Growth hormone, the insulin-like growth factor axis, insulin and cancer risk. Nat Rev Endocrinol (2010) 1.61

Insulin-like growth factor binding protein 2 promotes glioma development and progression. Proc Natl Acad Sci U S A (2007) 1.61

IGF-binding protein-2 protects against the development of obesity and insulin resistance. Diabetes (2007) 1.56

NOX4 mediates hypoxia-induced proliferation of human pulmonary artery smooth muscle cells: the role of autocrine production of transforming growth factor-{beta}1 and insulin-like growth factor binding protein-3. Am J Physiol Lung Cell Mol Physiol (2008) 1.52

Retinopathy of prematurity: understanding ischemic retinal vasculopathies at an extreme of life. J Clin Invest (2010) 1.49

Emerging therapeutic opportunities for skeletal restoration. Nat Rev Drug Discov (2011) 1.48

Severe preeclampsia-related changes in gene expression at the maternal-fetal interface include sialic acid-binding immunoglobulin-like lectin-6 and pappalysin-2. Endocrinology (2008) 1.47

Bi-compartmental communication contributes to the opposite proliferative behavior of Notch1-deficient hair follicle and epidermal keratinocytes. Development (2007) 1.46

The C terminus of p53 family proteins is a cell fate determinant. Mol Cell Biol (2005) 1.45

The role of insulin-like growth factor-I and its binding proteins in glucose homeostasis and type 2 diabetes. Diabetes Metab Res Rev (2009) 1.41

HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. Mol Cancer Ther (2008) 1.40

Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases? Pharmacol Rev (2010) 1.39

Induction of cellular senescence by insulin-like growth factor binding protein-5 through a p53-dependent mechanism. Mol Biol Cell (2007) 1.38

Hepatic IGFBP1 is a prosurvival factor that binds to BAK, protects the liver from apoptosis, and antagonizes the proapoptotic actions of p53 at mitochondria. Genes Dev (2007) 1.37

Understanding hypoxia-induced gene expression in early development: in vitro and in vivo analysis of hypoxia-inducible factor 1-regulated zebra fish insulin-like growth factor binding protein 1 gene expression. Mol Cell Biol (2006) 1.34

Insulin-like growth factor-binding protein-1 (IGFBP-1) mediates hypoxia-induced embryonic growth and developmental retardation. Proc Natl Acad Sci U S A (2005) 1.34

Interleukin-6 myokine signaling in skeletal muscle: a double-edged sword? FEBS J (2013) 1.33

Insulin-like growth factor binding protein-3 mediates vascular repair by enhancing nitric oxide generation. Circ Res (2009) 1.31

IGFBP-5 regulates muscle cell differentiation by binding to IGF-II and switching on the IGF-II auto-regulation loop. J Cell Biol (2008) 1.31

Defining the pathway to insulin-like growth factor system targeting in cancer. Biochem Pharmacol (2010) 1.31

The role of the insulin-like growth factor system in colorectal cancer: review of current knowledge. Int J Colorectal Dis (2005) 1.30

The glycolytic inhibitor 2-deoxyglucose activates multiple prosurvival pathways through IGF1R. J Biol Chem (2009) 1.30

Epidermal growth factor receptor regulates aberrant expression of insulin-like growth factor-binding protein 3. Cancer Res (2004) 1.28

Visceral adiposity, insulin resistance and cancer risk. Diabetol Metab Syndr (2011) 1.26

Serum complexes of insulin-like growth factor-1 modulate skeletal integrity and carbohydrate metabolism. FASEB J (2008) 1.23

Identification of a novel cell death receptor mediating IGFBP-3-induced anti-tumor effects in breast and prostate cancer. J Biol Chem (2010) 1.20

Clinical, agricultural, and evolutionary biology of myostatin: a comparative review. Endocr Rev (2008) 1.18

A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians. Hum Mol Genet (2010) 1.18

MicroRNA-21 promotes glioblastoma tumorigenesis by down-regulating insulin-like growth factor-binding protein-3 (IGFBP3). J Biol Chem (2014) 1.17

Disruption of insulin-like growth factor-I expression in type IIalphaI collagen-expressing cells reduces bone length and width in mice. Physiol Genomics (2007) 1.17

Insulin-like growth factor-binding protein-3 promotes transforming growth factor-{beta}1-mediated epithelial-to-mesenchymal transition and motility in transformed human esophageal cells. Carcinogenesis (2010) 1.17

Differential activation of insulin receptor substrates 1 and 2 by insulin-like growth factor-activated insulin receptors. Mol Cell Biol (2007) 1.15

Evolution of ancient functions in the vertebrate insulin-like growth factor system uncovered by study of duplicated salmonid fish genomes. Mol Biol Evol (2013) 1.13

Novel protective properties of IGFBP-3 result in enhanced pericyte ensheathment, reduced microglial activation, increased microglial apoptosis, and neuronal protection after ischemic retinal injury. Am J Pathol (2011) 1.12

Quantitative ontogeny of murine insulin-like growth factor (IGF)-I, IGF-binding protein-3 and the IGF-related acid-labile subunit. Growth Horm IGF Res (2007) 1.11

Structural basis for the inhibition of insulin-like growth factors by insulin-like growth factor-binding proteins. Proc Natl Acad Sci U S A (2006) 1.11

Targeting the insulin-like growth factor receptor pathway in lung cancer: problems and pitfalls. Ther Adv Med Oncol (2012) 1.10

Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach. J Med Chem (2009) 1.10

Something old, something new and something borrowed: emerging paradigm of insulin-like growth factor type 1 receptor (IGF-1R) signaling regulation. Cell Mol Life Sci (2013) 1.08

Insulin-like growth factor axis and risk of type 2 diabetes in women. Diabetes (2012) 1.08

The biological actions of dehydroepiandrosterone involves multiple receptors. Drug Metab Rev (2006) 1.08

Characterization of the equine skeletal muscle transcriptome identifies novel functional responses to exercise training. BMC Genomics (2010) 1.08

Insulin-like growth factor (IGF) binding protein-4 is both a positive and negative regulator of IGF activity in vivo. Mol Endocrinol (2008) 1.08

Thyroid hormone-mediated growth and differentiation of growth plate chondrocytes involves IGF-1 modulation of beta-catenin signaling. J Bone Miner Res (2010) 1.06

Targeting insulin and insulin-like growth factor pathways in epithelial ovarian cancer. J Oncol (2010) 1.06

Potentiation of growth factor signaling by insulin-like growth factor-binding protein-3 in breast epithelial cells requires sphingosine kinase activity. J Biol Chem (2009) 1.04

Biochemical characterization and N-terminomics analysis of leukolysin, the membrane-type 6 matrix metalloprotease (MMP25): chemokine and vimentin cleavages enhance cell migration and macrophage phagocytic activities. J Biol Chem (2012) 1.04

Reactivation of the insulin-like growth factor-II signaling pathway in human hepatocellular carcinoma. World J Gastroenterol (2008) 1.04

Mechanisms of fibroblast cell therapy for dystrophic epidermolysis bullosa: high stability of collagen VII favors long-term skin integrity. Mol Ther (2009) 1.03

Geniculocortical input drives genetic distinctions between primary and higher-order visual areas. Science (2013) 1.03

Differential modulation of Sonic-hedgehog-induced cerebellar granule cell precursor proliferation by the IGF signaling network. Dev Neurosci (2010) 1.03

The heparin-binding domain of IGFBP-2 has insulin-like growth factor binding-independent biologic activity in the growing skeleton. J Biol Chem (2011) 1.02

Diverse roles of growth hormone and insulin-like growth factor-1 in mammalian aging: progress and controversies. J Gerontol A Biol Sci Med Sci (2012) 1.02

Diabetes and cancer II: role of diabetes medications and influence of shared risk factors. Cancer Causes Control (2012) 1.01

Functional roles and clinical values of insulin-like growth factor-binding protein-5 in different types of cancers. Chin J Cancer (2012) 1.01

Circulating insulin-like growth factor axis and the risk of pancreatic cancer in four prospective cohorts. Br J Cancer (2007) 1.01

The multi-functional role of insulin-like growth factor binding proteins in bone. Pediatr Nephrol (2004) 1.01

Hormone replacement therapy and physical function in healthy older men. Time to talk hormones? Endocr Rev (2012) 1.01

Multifunctional roles of insulin-like growth factor binding protein 5 in breast cancer. Breast Cancer Res (2008) 1.01

Insulin-like growth factor binding proteins: a structural perspective. Front Endocrinol (Lausanne) (2012) 1.01

Transcriptional regulation of the IGF signaling pathway by amino acids and insulin-like growth factors during myogenesis in Atlantic salmon. PLoS One (2010) 1.00

Insulin biosynthesis in neuronal progenitors derived from adult hippocampus and the olfactory bulb. EMBO Mol Med (2011) 1.00

Pomegranate extract induces apoptosis in human prostate cancer cells by modulation of the IGF-IGFBP axis. Growth Horm IGF Res (2009) 1.00

Duplication and diversification of the hypoxia-inducible IGFBP-1 gene in zebrafish. PLoS One (2008) 0.99

FOXA1 promotes tumor progression in prostate cancer via the insulin-like growth factor binding protein 3 pathway. PLoS One (2012) 0.99

Novel roles of the IGF-IGFBP axis in etiopathophysiology of diabetic nephropathy. Diabetes Res Clin Pract (2006) 0.99

What's new in the IGF-binding proteins? Growth Horm IGF Res (2004) 0.99

Role of the retinal vascular endothelial cell in ocular disease. Prog Retin Eye Res (2012) 0.99

Modulation of insulin-like growth factor (IGF)-I and IGF-binding protein interactions enhances skeletal muscle regeneration and ameliorates the dystrophic pathology in mdx mice. Am J Pathol (2007) 0.98

Regulation of retinal endothelial cell apoptosis through activation of the IGFBP-3 receptor. Apoptosis (2013) 0.98

The IGF-I regulatory system and its impact on skeletal and energy homeostasis. J Cell Biochem (2010) 0.98

Influence of the hepatic eukaryotic initiation factor 2alpha (eIF2alpha) endoplasmic reticulum (ER) stress response pathway on insulin-mediated ER stress and hepatic and peripheral glucose metabolism. J Biol Chem (2011) 0.98

Proinflammatory and profibrotic mediators: principal effectors of leiomyoma development as a fibrotic disorder. Semin Reprod Med (2010) 0.98

IGFBP-3 regulates esophageal tumor growth through IGF-dependent and independent mechanisms. Cancer Biol Ther (2007) 0.97

Insulin-like growth factor (IGF) binding protein 2 functions coordinately with receptor protein tyrosine phosphatase β and the IGF-I receptor to regulate IGF-I-stimulated signaling. Mol Cell Biol (2012) 0.97

Duplication of the IGFBP-2 gene in teleost fish: protein structure and functionality conservation and gene expression divergence. PLoS One (2008) 0.97

Defining the cellular lineage hierarchy in the interfollicular epidermis of adult skin. Nat Cell Biol (2016) 0.96

Protein secretion is required for pregnancy-associated plasma protein-A to promote lung cancer growth in vivo. PLoS One (2012) 0.96

IGFBP-3, hypoxia and TNF-alpha inhibit adiponectin transcription. Biochem Biophys Res Commun (2009) 0.96

Association between serum IGF-1 and diabetes among U.S. adults. Diabetes Care (2010) 0.96

Insulin-like growth factor-binding protein-2 is required for osteoclast differentiation. J Bone Miner Res (2012) 0.95

The glycemic index of foods influences postprandial insulin-like growth factor-binding protein responses in lean young subjects. Am J Clin Nutr (2005) 1.75

Regulation of the growth hormone receptor/binding protein, insulin-like growth factor ternary complex system in human cirrhosis. J Hepatol (2002) 1.57

Within-subject variability and analytic imprecision of insulinlike growth factor axis and collagen markers: implications for clinical diagnosis and doping tests. Clin Chem (2008) 1.55

Regulation of the somatotropic axis by intensive insulin therapy during protracted critical illness. J Clin Endocrinol Metab (2004) 1.50

Insulin-like growth factor-binding protein-5 inhibits the growth of human breast cancer cells in vitro and in vivo. J Biol Chem (2003) 1.43

RSV604, a novel inhibitor of respiratory syncytial virus replication. Antimicrob Agents Chemother (2007) 1.34

Rapamycin treatment for a child with germline PTEN mutation. Nat Clin Pract Oncol (2008) 1.21

Greater drug injecting risk for HIV, HBV, and HCV infection in a city where syringe exchange and pharmacy syringe distribution are illegal. J Urban Health (2008) 1.18

Metformin rapidly increases insulin receptor activation in human liver and signals preferentially through insulin-receptor substrate-2. J Clin Endocrinol Metab (2003) 1.15

The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone. Clin Endocrinol (Oxf) (2002) 1.11

Proteomic profiling of cholangiocarcinoma: diagnostic potential of SELDI-TOF MS in malignant bile duct stricture. Hepatology (2006) 1.10

IGF-binding protein-3-induced growth inhibition and apoptosis do not require cell surface binding and nuclear translocation in human breast cancer cells. Endocrinology (2002) 1.07

Involvement of pregnancy-associated plasma protein-A2 in insulin-like growth factor (IGF) binding protein-5 proteolysis during pregnancy: a potential mechanism for increasing IGF bioavailability. J Clin Endocrinol Metab (2010) 1.07

Insulin-like growth factor binding protein-3 leads to insulin resistance in adipocytes. J Clin Endocrinol Metab (2005) 1.06

Inhibition of adipocyte differentiation by insulin-like growth factor-binding protein-3. Am J Physiol Endocrinol Metab (2009) 1.06

Insulin-like growth factor-binding protein-3 potentiates epidermal growth factor action in MCF-10A mammary epithelial cells. Involvement of p44/42 and p38 mitogen-activated protein kinases. J Biol Chem (2002) 1.05

Insulin-like growth factor binding protein-3 expression is associated with growth stimulation of T47D human breast cancer cells: the role of altered epidermal growth factor signaling. J Clin Endocrinol Metab (2004) 1.05

Potentiation of growth factor signaling by insulin-like growth factor-binding protein-3 in breast epithelial cells requires sphingosine kinase activity. J Biol Chem (2009) 1.04

Enhancement of tumor necrosis factor-alpha-induced growth inhibition by insulin-like growth factor-binding protein-5 (IGFBP-5), but not IGFBP-3 in human breast cancer cells. Endocrinology (2005) 1.04

Regulation of insulin-like growth factor binding protein-1 during protracted critical illness. J Clin Endocrinol Metab (2002) 1.02

Signaling through the Smad pathway by insulin-like growth factor-binding protein-3 in breast cancer cells. Relationship to transforming growth factor-beta 1 signaling. J Biol Chem (2001) 1.00

Free insulin-like growth factor binding protein-3 (IGFBP-3) reduces retinal vascular permeability in association with a reduction of acid sphingomyelinase (ASMase). Invest Ophthalmol Vis Sci (2011) 1.00

Nuclear insulin-like growth factor binding protein-3 induces apoptosis and is targeted to ubiquitin/proteasome-dependent proteolysis. Cancer Res (2006) 0.99

The chemokine CXCL1 induces proliferation in epithelial ovarian cancer cells by transactivation of the epidermal growth factor receptor. Endocr Relat Cancer (2010) 0.99

Novel biomarkers of human growth hormone action from serum proteomic profiling using protein chip mass spectrometry. J Clin Endocrinol Metab (2005) 0.99

Novel serum protein biomarker panel revealed by mass spectrometry and its prognostic value in breast cancer. Breast Cancer Res (2014) 0.98

Toward the development of a test for growth hormone (GH) abuse: a study of extreme physiological ranges of GH-dependent markers in 813 elite athletes in the postcompetition setting. J Clin Endocrinol Metab (2004) 0.98

Expression of insulin-like growth factor binding protein-2 by MCF-7 breast cancer cells is regulated through the phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway. Endocrinology (2007) 0.96

Insulin-like growth factor binding protein-3 prevents retinoid receptor heterodimerization: implications for retinoic acid-sensitivity in human breast cancer cells. Biochem Biophys Res Commun (2004) 0.95

1,4-benzodiazepines as inhibitors of respiratory syncytial virus. The identification of a clinical candidate. J Med Chem (2007) 0.95

Over expression of insulin-like growth factor binding protein 3 in clear cell renal cell carcinoma. J Urol (2008) 0.95

Breast cancer-associated fibroblasts induce epithelial-to-mesenchymal transition in breast cancer cells. Endocr Relat Cancer (2013) 0.94

Inhibition of insulin-like growth factor-binding protein-3 signaling through sphingosine kinase-1 sensitizes triple-negative breast cancer cells to EGF receptor blockade. Mol Cancer Ther (2013) 0.94

Biomarkers of breast cancer apoptosis induced by chemotherapy and TRAIL. J Proteome Res (2011) 0.93

Proteomic classification of pancreatic adenocarcinoma tissue using protein chip technology. Gastroenterology (2006) 0.92

Molecular basis of the interaction between IGFBP-3 and retinoid X receptor: role in modulation of RAR-signaling. Arch Biochem Biophys (2007) 0.91

Protection of blood retinal barrier and systemic vasculature by insulin-like growth factor binding protein-3. PLoS One (2012) 0.91

Phosphorylation of insulin-like growth factor binding protein-3 by deoxyribonucleic acid-dependent protein kinase reduces ligand binding and enhances nuclear accumulation. Endocrinology (2003) 0.90

1,4-Benzodiazepines as inhibitors of respiratory syncytial virus. J Med Chem (2006) 0.90

Signalling pathways of insulin-like growth factors (IGFs) and IGF binding protein-3. Growth Factors (2011) 0.90

Effect of maternal asthma, inhaled glucocorticoids and cigarette use during pregnancy on the newborn insulin-like growth factor axis. Growth Horm IGF Res (2009) 0.89

Insulin-like growth factor binding protein-5 interacts with the vitamin D receptor and modulates the vitamin D response in osteoblasts. Mol Endocrinol (2007) 0.89

Breast cancer biomarkers: proteomic discovery and translation to clinically relevant assays. Expert Rev Proteomics (2012) 0.88

Role of N- and C-terminal residues of insulin-like growth factor (IGF)-binding protein-3 in regulating IGF complex formation and receptor activation. J Biol Chem (2004) 0.88

Pharmacodynamics of growth hormone abuse biomarkers and the influence of gender and testosterone: a randomized double-blind placebo-controlled study in young recreational athletes. J Clin Endocrinol Metab (2008) 0.87

Activity of human pregnancy insulin-like growth factor binding protein-3: determination by reconstituting recombinant complexes. Endocrinology (2009) 0.87

The aminoterminal insulin-like growth factor (IGF) binding domain of IGF binding protein-3 cannot be functionally substituted by the structurally homologous domain of CCN3. Endocrinology (2006) 0.87

Insulin-like growth factor binding protein-3 inhibits migration of endometrial cancer cells. Cancer Lett (2011) 0.87

Impaired blockade of insulin-like growth factor I (IGF-I)-induced hypoglycemia by IGF binding protein-3 analog with reduced ternary complex-forming ability. Endocrinology (2002) 0.87

Amino- and carboxyl-terminal fragments of insulin-like growth factor (IGF) binding protein-3 cooperate to bind IGFs with high affinity and inhibit IGF receptor interactions. Endocrinology (2003) 0.86

Gonadotropin signalling in epithelial ovarian cancer. Cancer Lett (2012) 0.86

TGF-β-induced expression of IGFBP-3 regulates IGF1R signaling in human osteosarcoma cells. Mol Cell Endocrinol (2013) 0.86

Growth hormone rapidly induces resistin gene expression in white adipose tissue of spontaneous dwarf (SDR) rats. Endocrinology (2002) 0.85

Proteomic profiling of growth hormone-responsive proteins in human peripheral blood leukocytes. J Clin Endocrinol Metab (2009) 0.85

Insulin-like growth factor-I inhibits cell growth in the a549 non-small lung cancer cell line. Am J Respir Cell Mol Biol (2002) 0.84

Gonadotropin-induced ovarian cancer cell migration and proliferation require extracellular signal-regulated kinase 1/2 activation regulated by calcium and protein kinase C{delta}. Endocr Relat Cancer (2010) 0.83

Altered expression of members of the IGF-axis in clear cell renal cell carcinoma. Int J Oncol (2005) 0.83

Classification of pancreatic cystic lesions using SELDI-TOF mass spectrometry. ANZ J Surg (2007) 0.83

Effects of endogenous insulin-like growth factor binding protein-3 on cell cycle regulation in breast cancer cells. Growth Factors (2009) 0.82

Biochemical characterization of individual human glycosylated pro-insulin-like growth factor (IGF)-II and big-IGF-II isoforms associated with cancer. J Biol Chem (2012) 0.82

Differential effects of raloxifene and estrogen on body composition in growth hormone-replaced hypopituitary women. J Clin Endocrinol Metab (2011) 0.82

Does growth hormone allow more efficient nitrogen sparing in postoperative patients requiring parenteral nutrition? A double-blind, placebo-controlled randomised trial. Clin Nutr (2005) 0.82

Interaction between IGF binding protein-3 and TGFβ in the regulation of adipocyte differentiation. Endocrinology (2012) 0.82

Involvement of insulin-like growth factor-binding protein-3 in the effects of histone deacetylase inhibitor MS-275 in hepatoma cells. J Biol Chem (2011) 0.82

Age-dependent regulation of the acid-labile subunit in response to fasting-refeeding in rats. Endocrinology (2002) 0.81

iTRAQ-based proteomic profiling of breast cancer cell response to doxorubicin and TRAIL. J Proteome Res (2012) 0.81

Protein chip discovery of secreted proteins regulated by the phosphatidylinositol 3-kinase pathway in ovarian cancer cell lines. Cancer Res (2006) 0.81

Growth hormone modulation of the rat hepatic bile transporter system in endotoxin-induced cholestasis. Endocrinology (2003) 0.80

The role of the acid-labile subunit in regulating insulin-like growth factor transport across human umbilical vein endothelial cell monolayers. J Clin Endocrinol Metab (2004) 0.80

Profiling of apoptotic changes in human breast cancer cells using SELDI-TOF mass spectrometry. Cell Physiol Biochem (2007) 0.80

The in vivo phosphorylation and glycosylation of human insulin-like growth factor-binding protein-5. Mol Cell Proteomics (2007) 0.79

Factors that may influence the willingness of cancer patients to consent for biobanking. Biopreserv Biobank (2014) 0.79

The effect of different patterns of growth hormone administration on the IGF axis and somatic and skeletal growth of the dwarf rat. Am J Physiol Endocrinol Metab (2009) 0.79

A study of parenteral versus enteral nutrition following caecal ligation and puncture in the rat: Influence on survival and tissue protein turnover. Clin Nutr (2004) 0.78

D440N mutation in the acid-labile subunit of insulin-like growth factor complexes inhibits secretion and complex formation. Mol Endocrinol (2010) 0.77

Modulatory effect of raloxifene and estrogen on the metabolic action of growth hormone in hypopituitary women. J Clin Endocrinol Metab (2010) 0.77

Discovery of diagnostic biomarkers for pancreatic cancer in immunodepleted serum by SELDI-TOF MS. Pancreatology (2012) 0.77

Postnatal nutrition alters body composition in adult offspring exposed to maternal protein restriction. Br J Nutr (2008) 0.76

Involvement of the insulin-like growth factor binding proteins in the cancer cell response to DNA damage. J Cell Commun Signal (2015) 0.76

CCN2 requires TGF-β signalling to regulate CCAAT/enhancer binding proteins and inhibit fat cell differentiation. J Cell Commun Signal (2014) 0.75

Regulation of the acid-labile subunit in sustained endotoxemia. Am J Physiol Endocrinol Metab (2002) 0.75

The circulating IGF system and its relationship with 24-h glucose regulation and insulin sensitivity in healthy subjects. Clin Endocrinol (Oxf) (2003) 0.75